Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 107M P/E - EPS this Y 49.40% Ern Qtrly Grth -
Income -52.16M Forward P/E 9.60 EPS next Y -24.40% 50D Avg Chg 20.00%
Sales 1.46M PEG 0.19 EPS past 5Y - 200D Avg Chg 18.00%
Dividend N/A Price/Book 0.99 EPS next 5Y -76.70% 52W High Chg -15.00%
Recommedations 1.70 Quick Ratio 27.62 Shares Outstanding 67.43M 52W Low Chg 102.00%
Insider Own 20.43% ROA -12.03% Shares Float 43.36M Beta 1.45
Inst Own 57.90% ROE -23.20% Shares Shorted/Prior 7.14M/6.95M Price 0.38
Gross Margin 100.00% Profit Margin - Avg. Volume 278,531 Target Price 22.63
Oper. Margin -2,711.60% Earnings Date - Volume 145,041 Change 0.00%
About IsoRay, Inc.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

IsoRay, Inc. News
07:15 AM Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
11/16/24 Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025?
11/15/24 Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
11/12/24 Perspective Therapeutics: Q3 Earnings Snapshot
11/12/24 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results
10/31/24 Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results
10/29/24 Perspective Therapeutics to Participate in Upcoming Investor Conferences in November
10/23/24 Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine
10/16/24 Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey
10/12/24 Perspective Therapeutics, Inc (CATX): A Small-Cap Pioneer in Targeted Cancer Therapies
10/11/24 Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research
10/10/24 Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
10/07/24 Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day
09/30/24 Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine
09/10/24 Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024
09/05/24 Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma
08/28/24 Perspective Therapeutics to Participate in Upcoming Investor Conferences in September
08/13/24 Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?
08/12/24 Perspective Therapeutics: Q2 Earnings Snapshot
08/12/24 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results
CATX Chatroom

User Image JDinvestments Posted - 53 minutes from now

$CATX https://stocks.apple.com/AwTsorMeoRsS_wsVFELWjFQ

User Image rughead64 Posted - 22 minutes from now

$CATX press usually comes out at 7 AM. I'm assuming they will put out the data result PR at 7

User Image TheStickerGuy Posted - 10 hours ago

$CATX I just figured out what this stock price needs. MOAR Decimals!! That's the ticket!

User Image SDBiotechInvestor Posted - 11 hours ago

$CATX - looking for something in line or similar to India data tomorrow. Could significantly boost the stock imo.

User Image Sanskrit Posted - 11 hours ago

$CATX LNTH just pulled out of a parallel descent by announcing a share repurchase program. Intersting that this is what it takes right now.

User Image TheStickerGuy Posted - 13 hours ago

$CATX Here's my therapy. Short this thing into the ground. (oh wait, someone has beaten me to it) Who's grand idea was it to do the consolidation? Who did it help? Wasn't me I can tell you that.

User Image Miura1957 Posted - 14 hours ago

$CATX if these boners would stop selling, they would force the 8M short shares to cover…unless they are all in on it…Mr spoor has a lot of explaining to do tomorrow, hope they are prepared. The response must be strong with no room for doubt.

User Image SDBiotechInvestor Posted - 14 hours ago

$CATX - if this can replicate the India trial ORR tomorrow, I think a huge pop is coming.

User Image Needs_Improvement Posted - 14 hours ago

$CATX can’t help it…bought 1500 shares at 6.09. I’ll gamble.

User Image Newmoves Posted - 15 hours ago

$CATX what an abomination all gains totally wiped out. What a shame. The same people have been in the stock forever. Keep on believing and never learn.

User Image morty104 Posted - 15 hours ago

$CATX I ain’t skeered

User Image Sanskrit Posted - 15 hours ago

$CATX Self-perpetuating, at this point. Buyers rewarded for holding out. Tomorrow will have to be pretty positive to cauterize this and stop the shock.

User Image Longswing Posted - 15 hours ago

$CATX WOW! And many of you cursed me for stating the truth. No profit in curing.

User Image jjohn1971 Posted - 15 hours ago

$CATX About to drop sub-$0.60 pre-split

User Image jj1287 Posted - 15 hours ago

$CATX another -10% day😂😂😂. Is that 5 in a row!!

User Image luke_trader Posted - 16 hours ago

$CATX this is unreal!

User Image chromeal5 Posted - 16 hours ago

$CATX Trump Bump. This is what you voted for.

User Image Miura1957 Posted - 16 hours ago

$CATX 2 weeks, 1/2 of the value incinerated

User Image Sayknee Posted - 16 hours ago

$CATX Well lets say the naysayers are right ( their not). The deep state and Military industrial complex are not just going to let Trump get into office. When the nukes start flying overhead , does the share price really matter..Everything will be pretty much shitville. Crazy times..Wish you all the best of luck!

User Image markbass2341 Posted - 16 hours ago

$CATX where is this going ?? Back to 2 bucks

User Image Ginopepino Posted - 16 hours ago

$CATX well I’ll be damned.

User Image Neptun2000 Posted - 16 hours ago

$CATX so annoying every day see it by -10% on the best times we didn’t saw +10% for sure something happening 😭

User Image TraderAmerica Posted - 17 hours ago

$CATX https://www.thegazette.com/business/targeting-tumors/

User Image SDBiotechInvestor Posted - 17 hours ago

$CATX - bought some shares today. Feels like it's just a generalist fund being blown out after RFK announcement.

User Image Luckiest_Man_Alive Posted - 17 hours ago

$CATX Going In at 6.25 $ Wish me luck ! 🍀🍀🍀🍀🍀🍀🍀 7️⃣7️⃣7️⃣

User Image TraderAmerica Posted - 17 hours ago

$CATX I would love to see these short sellers running to cover their positions.

User Image st6387 Posted - 17 hours ago

$CATX Concerned if this thing drops below $5 what the implications are of institutions’ continued ability to hold shares. This was the main reason for RS was to enable institutions to invest in something that was no longer a penny stock.

User Image Sayknee Posted - 17 hours ago

$CATX 2 days to report…Not one share sold by insider.

User Image ltcman Posted - 18 hours ago

$CATX never thought we would see $0.63 again!

User Image Filbert3 Posted - 18 hours ago

$CATX the volume is not low for the past few days right?

Analyst Ratings
Wedbush Outperform Oct 1, 24
Truist Securities Buy Sep 25, 24
Cantor Fitzgerald Overweight Sep 10, 24
Cantor Fitzgerald Overweight Sep 9, 24
Cantor Fitzgerald Overweight Sep 6, 24
Cantor Fitzgerald Overweight Sep 3, 24
RBC Capital Outperform Aug 16, 24
Oppenheimer Outperform Aug 13, 24
B of A Securities Buy Jul 25, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Williamson Robert F III Director Director Jan 30 Buy 0.71 127,206 90,316 338,761 02/01/24
Williamson Robert F III Director Director Jan 26 Buy 0.6 135,879 81,527 211,555 01/30/24
Puhlmann Markus Chief Medical Office.. Chief Medical Officer Jan 24 Buy 0.49960 280,000 139,888 1,375,425 01/26/24
Williamson Robert F III Director Director Jan 24 Buy 0.49 51,996 25,478 75,676 01/26/24
Williamson Robert F III Director Director Dec 21 Buy 0.3283 3,663 1,203 3,663 12/26/23
Hunt Jonathan Robert Chief Financial Offi.. Chief Financial Officer Dec 18 Buy 0.2587 125,000 32,338 316,710 12/19/23
Williamson Robert F III Director Director Dec 18 Buy 0.29 23,680 6,867 23,680 12/19/23
Puhlmann Markus Chief Medical Office.. Chief Medical Officer Dec 15 Buy 0.29 595,425 172,673 1,095,425 12/19/23
Woods Lori A Director Director Apr 13 Option 0.61 187,500 114,375 1,334,538 04/19/23
Hunt Jonathan Robert Chief Financial Offi.. Chief Financial Officer Dec 01 Buy 0.38 85,404 32,454 191,710 12/05/22
Streeter Jennifer COO & VP of HR COO & VP of HR Aug 18 Option 0.43 50,000 21,500 87,940 08/19/22
Streeter Jennifer COO & VP of HR COO & VP of HR Aug 05 Option 0.33 22,500 7,425 27,940 08/10/22
Austin Mark John VP Finance/Prin Fin&.. VP Finance/Prin Fin&Acct Offic Jun 08 Buy 0.29 18,800 5,452 54,030 06/09/22
Woods Lori A CEO CEO Jun 07 Buy 0.29640 75,000 22,230 1,047,038 06/09/22
Hunt Jonathan Robert Chief Financial Offi.. Chief Financial Officer Jun 07 Buy 0.28 39,000 10,920 106,306 06/09/22
Woods Lori A CEO CEO Nov 23 Option 0.45 125,000 56,250 972,038 11/24/21